BX-795

Catalog No.S1274

BX-795 Chemical Structure

Molecular Weight(MW): 591.47

BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.

Size Price Stock Quantity  
USD 150 In stock
USD 320 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) Washed human platelets were untreated or pretreated with the PDK1 inhibitor BX-795 (1 μM) for 5 min, and this was followed by stimulation with 2-methylthio-ADP (2MeSADP) (50 nM) under stirring for 5 min. Western blots were then probed for phosphorylated Akt (Thr308), Akt (Ser473), glycogen synthase kinase 3b (GSK3b) (Ser9), mitogen-activated protein kinase kinase 1/2 (MEK1/2) (Ser217/221), extracellular signal-regulated kinase 1/2 (ERK1/2) (Thr202/Tyr204), and cytosolic phospholipase A2 (cPLA2) (Ser505). The western blots shown are representative of three independent experiments.

    J Thromb Haemost, 2018, 16(6):1211-1225. BX-795 purchased from Selleck.

    Induction of basal p62 Ser403 phosphorylation in ULK1/2-deficient MEF was suppressed by BX-795, an inhibitor of TBK1. WT ( Ulk1 +/+/Ulk2 +/+) and Ulk1 -/- /Ulk2 -/-(KO) MEF were treated with NaCl/Pi (Con) or 10 uM BX-795 for 6 h, and subjected to immunoblotting with indicated antibodies.

    FEBS J 2014 281(17), 3816-27. BX-795 purchased from Selleck.

  • Virology 2014 450-451, 182-95. BX-795 purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 3.33 μM or 10 μM inhibitors (BX795 or CCT128930) in three-dimensional cell culture for 24 hours. Ten percent fetal bovine serum was used in A and B.

    PLoS One, 2016, 11(5):e0155052. . BX-795 purchased from Selleck.

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Description BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.
Targets
PDK-1 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
CDK2/CyclinE [1]
(Cell-free assay)
Chk1 [1]
(Cell-free assay)
6 nM 320 nM 430 nM 510 nM
In vitro

BX-795 effectively blocks PDK1 activity in PC-3 cells, as shown by their ability to block phosphorylation of S6K1, Akt, PKCδ, and GSK3β. BX-795 potently inhibits tumor cell growth on plastic with IC50 of 1.6, 1.4, and 1.9 μM for MDA-468, HCT-116 and MiaPaca cells, respectively. In soft agar, BX-795 displays higher growth inhibition with IC50 of 0.72, and 0.25 μM for MDA-468, and PC-3 cells, respectively. [1] In addition, BX-795, as an inhibitor of the TBK1/IKKɛ, blocks TBK1- and IKKε-mediated activation of IRF3 and production of IFN-β. [2] In platelet physiological responses, BX795 produces inhibitory effect on 2-MeSADP-induced or collagen-induced aggregation, ATP secretion and thromboxane generation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV-4-11 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NW\X[I5TUW6qaXLpeIlwdiCxZjDoeY1idiCPVj20MVEyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzZwODDuUS=> Mn;1V2FPT0WU
KRX cells MmniSpVv[3Srb36gZZN{[Xl? NHTFWGo4KG2rboO= M3e1c2lvcGmkaYTpc44hd2ZiU2XNU{11[WepZXSgWWxMOSBqdX7rco94diCxcnnnbY4qKGurbnHz[UBld22jaX6g[ZhxemW|c3XkJIlvKEuUWDDj[YxteyC3c3nu[{BcOzKSXT3nZY1u[S2DVGCgZY5lKG27ZXzpckBj[XOrYzDwdo91\WmwIIP1ZpN1emG2ZTDpcoN2[mG2ZXSg[o9zKDdibXnudy=> MV:yOlI4PTZ6MR?=
human NKM-1 cell M3fB[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIDGSHBKdmirYnn0bY9vKG:oIHj1cYFvKE6NTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PjF7NDFOwG0> NUnuNI03W0GQR1XS
human P30-OHK cell NVXCWI9ET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1T4cmlvcGmkaYTpc44hd2ZiaIXtZY4hWDNyLV;IT{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7LDDJR|UxRTBwNEm2OUDPxE1? NFvsT4NUSU6JRWK=
human YH-13 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3jM[mlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlYzQDh6IN88US=> MVXTRW5ITVJ?
human LXF-289 cell MnvvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVjne2dlUW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwIFnDOVA:OC54NU[5N{DPxE1? M1vVUXNCVkeHUh?=
human BE-13 cell NV6zNo13T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEL0dWtKdmirYnn0bY9vKG:oIHj1cYFvKEKHLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44ODR5NzFOwG0> M4jM[HNCVkeHUh?=
human RS4-11 cell NGS5T4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFrSUJBKdmirYnn0bY9vKG:oIHj1cYFvKFKVND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzJ3OUSg{txO MVHTRW5ITVJ?
human A3-KAW cell MnvKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXrJcohq[mm2aX;uJI9nKGi3bXHuJGE{NUuDVzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|MxPTVizszN NYDZd2RSW0GQR1XS
human PA-1 cell M{HCcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkiwOFIzKM7:TR?= MUPTRW5ITVJ?
human ES7 cell NGG2ZXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHXSeYVKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFM2PjZizszN M3PVWXNCVkeHUh?=
human ES8 cell NELBWJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkjLTY5pcWKrdHnvckBw\iCqdX3hckBGWzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki0N|M3KM7:TR?= NIHOVlZUSU6JRWK=
human SW982 cell NFjxUHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUnJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65OVEzPCEQvF2= MVvTRW5ITVJ?
human VA-ES-BJ cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mnu3TY5pcWKrdHnvckBw\iCqdX3hckBXSS2HUz3CTkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTh2Nkeg{txO M2\IS3NCVkeHUh?=
human 697 cell MnfqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH3afY9KdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNFE3OjNizszN M13QOXNCVkeHUh?=
human MOLT-4 cell MlnQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWLJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNFMzPDRizszN M121PXNCVkeHUh?=
human D-283MED cell M2nFbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVTPXHhUUW6qaXLpeIlwdiCxZjDoeY1idiCGLUK4N21GTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMEO5OFgh|pyv NYXRXFNjW0GQR1XS
human ALL-PO cell NULLRo9vT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGFNVC2STzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNFYxPzNizszN M2TYOXNCVkeHUh?=
human NB14 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M374SWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNFYxQDFizszN M1H5PXNCVkeHUh?=
human NTERA-S-cl-D1 cell NVvZeZZlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVPJcohq[mm2aX;uJI9nKGi3bXHuJG5VTVKDLWOtZ4wuTDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC3O|c2KM7:TR?= MWfTRW5ITVJ?
human BFTC-905 cell MlHyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn25TY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODhzMEGg{txO MlP6V2FPT0WU
human H4 cell NH7oemhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4HT[WlvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkGwNlAyKM7:TR?= MW\TRW5ITVJ?
human CHP-212 cell MlzNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVLJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlE1ODN5IN88US=> NEK1OZVUSU6JRWK=
human A204 cell NEfoZXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVXJcohq[mm2aX;uJI9nKGi3bXHuJGEzODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkG1OFY4KM7:TR?= M2XBRnNCVkeHUh?=
human NB69 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4LBZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVU5PjVizszN MVXTRW5ITVJ?
human P12-ICHIKAWA cell MmjjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2nyZmlvcGmkaYTpc44hd2ZiaIXtZY4hWDF{LVnDTGlMSVeDIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6xPFE4OSEQvF2= MUTTRW5ITVJ?
human L-363 cell M3;ZbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHTmRlhKdmirYnn0bY9vKG:oIHj1cYFvKExvM{[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yQDF7NzFOwG0> M3WyeXNCVkeHUh?=
human ES5 cell MliwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NITCcYNKdmirYnn0bY9vKG:oIHj1cYFvKEWVNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVk{PTRizszN M4PqNHNCVkeHUh?=
human CAL-51 cell NIO3[4JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWDLTnYxUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ{MUW2JO69VQ>? NXq3coViW0GQR1XS
human NBsusSR cell NYDMSVFWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGjXWFRKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ2NUe4JO69VQ>? NUTDSWo3W0GQR1XS
human HOP-92 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3nvcmlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SLUmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zPzJ7MzFOwG0> MUPTRW5ITVJ?
human DU-4475 cell MonaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4\OXGlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjl{NEWg{txO NULu[oJtW0GQR1XS
human LB1047-RCC cell NEi1c3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlzTTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OUK4NUDPxE1? NYrzVIY{W0GQR1XS
human D-566MG cell MnrrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFvVWmhKdmirYnn0bY9vKG:oIHj1cYFvKERvNU[2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjNyNES4JO69VQ>? NWXlT3NPW0GQR1XS
human A375 cell MmfFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYjrXJNlUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{ODh3ODFOwG0> M1zSOHNCVkeHUh?=
human ATN-1 cell MlTuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1jWZmlvcGmkaYTpc44hd2ZiaIXtZY4hSVSQLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM4OTh3IN88US=> Mkf4V2FPT0WU
human M059J cell NHXGSWFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUTJcohq[mm2aX;uJI9nKGi3bXHuJG0xPTmMIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zO|Y2OiEQvF2= NFr5fnlUSU6JRWK=
human HSC-3 cell M{O0ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGDPZY9KdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PDJyODFOwG0> MXTTRW5ITVJ?
human DOHH-2 cell M1vwPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVLJcohq[mm2aX;uJI9nKGi3bXHuJGRQUEhvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFU5OTRizszN MkDrV2FPT0WU
human G-402 cell MkLLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUPJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT60OlUzPSEQvF2= NIDUcpBUSU6JRWK=
human LC-2-ad cell NH;vT5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1LwTmlvcGmkaYTpc44hd2ZiaIXtZY4hVENvMj3h[EBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDdzM{Kg{txO M1y5PXNCVkeHUh?=
human LOXIMVI cell M3OxTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJGxQYEmPVlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlUxPTV{IN88US=> MmL0V2FPT0WU
human DK-MG cell M3uzdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mkn2TY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVczQThizszN MX7TRW5ITVJ?
human HOS cell MnHPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVe5VFV1UW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU4OzB7IN88US=> NH[0SHBUSU6JRWK=
human BHT-101 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkLuTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42Pzh5NzFOwG0> MVPTRW5ITVJ?
human U-2-OS cell NXH2fZp3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M170N2lvcGmkaYTpc44hd2ZiaIXtZY4hXS1{LV;TJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42QDhyNjFOwG0> MYrTRW5ITVJ?
human D-423MG cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGQuPDJ|TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYxQDB4IN88US=> NXOwZ|BjW0GQR1XS
human AN3-CA cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYfxOoVsUW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZ|OUmxJO69VQ>? NVW1bXhUW0GQR1XS
human TE-11 cell NELHOnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjxd|hQUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjV{ODFOwG0> NHPxZnhUSU6JRWK=
human SK-NEP-1 cell NUH3XWp[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnLlTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QRWCtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjV|N{[g{txO MV7TRW5ITVJ?
human MG-63 cell MlnJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{TSfWlvcGmkaYTpc44hd2ZiaIXtZY4hVUdvNkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY5PTZ5IN88US=> M4q5WHNCVkeHUh?=
human RH-1 cell MlnsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF\xNmJKdmirYnn0bY9vKG:oIHj1cYFvKFKKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlcxOjd2IN88US=> MoKzV2FPT0WU
human MDA-MB-157 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUPJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjdzNke0JO69VQ>? Mnq0V2FPT0WU
human A427 cell Ml\DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlTjTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT63N|U5QSEQvF2= NHSxRllUSU6JRWK=
human ES1 cell NX;O[YpiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MojKTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLke1OFUyKM7:TR?= MorZV2FPT0WU
human C32 cell M3;hc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVjjc5JOUW6qaXLpeIlwdiCxZjDoeY1idiCFM{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc3OzlizszN NXHk[VlNW0GQR1XS
human LAMA-84 cell M2W4PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJGxCVUFvOESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc3QDd{IN88US=> MV\TRW5ITVJ?
human YKG-1 cell NIfuVYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYDJcohq[mm2aX;uJI9nKGi3bXHuJHlMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT63O|EzPCEQvF2= MVzTRW5ITVJ?
human NCI-H1048 cell MnvES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NELiTZZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVA1QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwN{i1NFkh|ryP NGi3XHJUSU6JRWK=
human KS-1 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{e4SmlvcGmkaYTpc44hd2ZiaIXtZY4hU1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPFI6QCEQvF2= NHWycFJUSU6JRWK=
human JVM-3 cell NYT6TZpwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFHT[JlKdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45PjR7MTFOwG0> Mln0V2FPT0WU
human GI-ME-N cell NUDHdWZVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVrCN482UW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56NkWzJO69VQ>? MlPYV2FPT0WU
human GT3TKB cell NHjzcmhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn[5TY5pcWKrdHnvckBw\iCqdX3hckBIXDOWS1KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg6PjR{IN88US=> M1ns[3NCVkeHUh?=
human CHL-1 cell M4HBTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmLqTY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVI{PzlizszN M4rpRnNCVkeHUh?=
human CHP-134 cell M1SzT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH7RTFdKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2xN|Qh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjl2NE[3JO69VQ>? NHHGO2RUSU6JRWK=
human 8-MG-BA cell NX;tVXZvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVrJcohq[mm2aX;uJI9nKGi3bXHuJFguVUdvQlGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk2PzR2IN88US=> M1vZZ3NCVkeHUh?=
human HO-1-N-1 cell M2jBOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M37mZ2lvcGmkaYTpc44hd2ZiaIXtZY4hUE9vMT3OMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjl5MUG3JO69VQ>? M4\6OnNCVkeHUh?=
human SW1088 cell M3zBemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIjwT2VKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTl4N{Og{txO M2T2O3NCVkeHUh?=
human SW48 cell NWr6UlVRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGfsZlhKdmirYnn0bY9vKG:oIHj1cYFvKFOZNEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlAzODZ5IN88US=> NVzwcJQ2W0GQR1XS
human VM-CUB-1 cell NYDVSWJwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWfJcohq[mm2aX;uJI9nKGi3bXHuJHZONUOXQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4xPDFzOTFOwG0> M2XzXnNCVkeHUh?=
human COLO-800 cell Mk[2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFjFcmpKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tPFAxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yNUGzOkDPxE1? M3P1NHNCVkeHUh?=
human TI-73 cell NFzS[HZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlLMTY5pcWKrdHnvckBw\iCqdX3hckBVUS15MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVE{QTlizszN M3OwcXNCVkeHUh?=
human HN cell M2Hs[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1Lx[2lvcGmkaYTpc44hd2ZiaIXtZY4hUE5iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkGyNVk5KM7:TR?= MX\TRW5ITVJ?
human DB cell MmXrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoLRTY5pcWKrdHnvckBw\iCqdX3hckBFSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMUK2N|Eh|ryP M4DreXNCVkeHUh?=
human Ca9-22 cell M3Xle2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVT1OZZRUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjF{OES3JO69VQ>? M{DTcXNCVkeHUh?=
human A549 cell MmXxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlzWTY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6xN|gxQCEQvF2= NH72[GlUSU6JRWK=
human KGN cell MlLsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGi3bXHuJGtIViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMkK1PVUh|ryP MojuV2FPT0WU
human BCPAP cell MmDXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2nD[mlvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI{OTV6IN88US=> NGn1NmdUSU6JRWK=
human Ramos-2G6-4C10 cell NGC3eZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NG\jVZRKdmirYnn0bY9vKG:oIHj1cYFvKFKjbX;zMVJIPi12Q{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zOzd3OTFOwG0> MVXTRW5ITVJ?
human OVCAR-5 cell M4PI[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3nJN2lvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjd5M{Sg{txO M1ywRXNCVkeHUh?=
human KG-1 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlPYTY5pcWKrdHnvckBw\iCqdX3hckBMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yO|c6OiEQvF2= MoC5V2FPT0WU
human CAKI-1 cell MnHiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVe5d3d7UW6qaXLpeIlwdiCxZjDoeY1idiCFQVvJMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjJ6MEW4JO69VQ>? M3rhXHNCVkeHUh?=
human QIMR-WIL cell Mn7LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXvuZ|dpUW6qaXLpeIlwdiCxZjDoeY1idiCTSV3SMXdKVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMki3OFQh|ryP M4\hbHNCVkeHUh?=
human SW1710 cell M2jwZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1LnOWlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zQTF2MjFOwG0> NELjfJdUSU6JRWK=
human SK-UT-1 cell NGLxeZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{DE[GlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvVWStNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjl|M{mg{txO NGPtZXpUSU6JRWK=
human IST-SL1 cell NV;4TI1JT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUTRTphPUW6qaXLpeIlwdiCxZjDoeY1idiCLU2StV2wyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5|MkG3OEDPxE1? M{XONHNCVkeHUh?=
human SW962 cell M3XLOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXO3bFlyUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m2NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOzN5NUeg{txO MmKxV2FPT0WU
human EM-2 cell NGjWbJVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1;oN2lvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuN|U{OzdizszN MWTTRW5ITVJ?
human D-263MG cell NV;5c2RWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlH4TY5pcWKrdHnvckBw\iCqdX3hckBFNTJ4M13HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{QDN{NzFOwG0> MnzZV2FPT0WU
human T98G cell M4nDOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWKzS2dOUW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{QDh3NzFOwG0> NYLz[m5oW0GQR1XS
human CTB-1 cell NGfMOlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGfwfFhKdmirYnn0bY9vKG:oIHj1cYFvKEOWQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{QTd4MTFOwG0> NFzN[ZVUSU6JRWK=
human Hs-578-T cell NIHM[2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFHPSJZKdmirYnn0bY9vKG:oIHj1cYFvKEi|LUW3PE1VKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi52MUW4O{DPxE1? M1rnN3NCVkeHUh?=
human SF126 cell NXPBVIxQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmDBTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOFM3OjFizszN NHf5bFlUSU6JRWK=
human NCI-H460 cell Mk\yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXnSVVVTUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ3OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNEO5OVUh|ryP NH3iWlVUSU6JRWK=
human NCI-H1755 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NET6TmJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc2PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUSwOFMh|ryP M3fOcnNCVkeHUh?=
human HL-60 cell M2LETWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWHJcohq[mm2aX;uJI9nKGi3bXHuJGhNNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61OFE2QSEQvF2= NXSxe|BQW0GQR1XS
human G-401 cell NVHKN|JlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnPMTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVYxQTlizszN NHi4XJZUSU6JRWK=
human AGS cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXrJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNU[yOVch|ryP NECwfY1USU6JRWK=
human HuO9 cell NF3mRnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2\tZWlvcGmkaYTpc44hd2ZiaIXtZY4hUHWROTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVY1PTZizszN NXLOflF{W0GQR1XS
human MFE-280 cell NGr6RolIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX\Rb4pQUW6qaXLpeIlwdiCxZjDoeY1idiCPRlWtNlgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53Nk[4OkDPxE1? MlnFV2FPT0WU
human NCI-H292 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42Pzd{MjFOwG0> MXjTRW5ITVJ?
human HuO-3N1 cell MmroS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MULJcohq[mm2aX;uJI9nKGi3bXHuJGh2Vy1|TkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlYxOzB5IN88US=> M1LycHNCVkeHUh?=
human ES3 cell M1\ObWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml64TY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[yNlg2KM7:TR?= M2HsXnNCVkeHUh?=
human LB2241-RCC cell MnjVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVPJcohq[mm2aX;uJI9nKGi3bXHuJGxDOjJ2MT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjZ7MEe5JO69VQ>? MWTTRW5ITVJ?
human NCI-H1155 cell M{XCbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2nCNGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNVU2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54OUSwOUDPxE1? NHfZd25USU6JRWK=
human SW872 cell NIjqZmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEnBbpRKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44ODZ5NjFOwG0> M2fYbHNCVkeHUh?=
human MHH-ES-1 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGThdphKdmirYnn0bY9vKG:oIHj1cYFvKE2KSD3FV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi55Mk[zN{DPxE1? MmS0V2FPT0WU
human KYSE-150 cell MnfES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV3OU|l5UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVE2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwN{K5O{DPxE1? M3\RfHNCVkeHUh?=
human MC-IXC cell MoLNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVPJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFk2OyEQvF2= NXu0fJpYW0GQR1XS
human HCC1187 cell NUjWfoZkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4\m[mlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUG4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDl4N{eg{txO NH;IcpNUSU6JRWK=
human UMC-11 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUPJcohq[mm2aX;uJI9nKGi3bXHuJHVOSy1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPVA1PzdizszN Mme5V2FPT0WU
human NB5 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4DKUmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj65N|cyPSEQvF2= NHPjWJJUSU6JRWK=
human A2058 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkfaTY5pcWKrdHnvckBw\iCqdX3hckBCOjB3ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPVc5PDRizszN NF75cGRUSU6JRWK=
human Becker cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlG1TY5pcWKrdHnvckBw\iCqdX3hckBD\WOtZYKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlAyOTF{IN88US=> M37tbnNCVkeHUh?=
human CAS-1 cell MlXjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NY\lRlNmUW6qaXLpeIlwdiCxZjDoeY1idiCFQWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODF3Nkmg{txO MnXmV2FPT0WU
human SW780 cell NG\LeoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2fUWmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI2PjB7IN88US=> MmfjV2FPT0WU
human KM12 cell M{nxTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoTjTY5pcWKrdHnvckBw\iCqdX3hckBMVTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6zNFE{OiEQvF2= MVLTRW5ITVJ?
human PC-3 cell M3HBfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4XBTWlvcGmkaYTpc44hd2ZiaIXtZY4hWENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNVc1OTFizszN M1fvOHNCVkeHUh?=
human A253 cell NV31SJN4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkXYTY5pcWKrdHnvckBw\iCqdX3hckBCOjV|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xPFg6OyEQvF2= MYHTRW5ITVJ?
human NB10 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkKyO|c{KM7:TR?= Mn3YV2FPT0WU
human A172 cell M1fUOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXTJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkS0OVch|ryP NU\VVGg2W0GQR1XS
human A498 cell NFu0doxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYDJcohq[mm2aX;uJI9nKGi3bXHuJGE1QThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkW2N|g{KM7:TR?= NXnOeGVIW0GQR1XS
human SW1573 cell NFz6dXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEXIN4pKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUW3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvQTB2OUGg{txO MoPHV2FPT0WU
human 5637 cell M{TGSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3z6OGlvcGmkaYTpc44hd2ZiaIXtZY4hPTZ|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNFc6ODRizszN NFHvfJlUSU6JRWK=
human A388 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MT6xN|k5KM7:TR?= MWfTRW5ITVJ?
human U251 cell M1vtW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHH3RXZKdmirYnn0bY9vKG:oIHj1cYFvKFV{NUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPE4yOTd3IN88US=> MofmV2FPT0WU

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-33P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-33P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.
Cell Research:[1]
+ Expand
  • Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells
  • Concentrations: ~10 μM
  • Incubation Time: 72 hours
  • Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.07 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG +2% Tween 80+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 591.47
Formula

C23H26IN7O2S

CAS No. 702675-74-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S1274 for animal studies?

  • Answer:

    We recommend to use the vehicle 2% DMSO+30% PEG +2% Tween 80+ddH2O for in vivo study.

PDK Signaling Pathway Map

Related PDK Products0

Tags: buy BX-795 | BX-795 supplier | purchase BX-795 | BX-795 cost | BX-795 manufacturer | order BX-795 | BX-795 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID